All NewsEducationTV
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Goldman Sachs Alternatives buys control of Italian medtech firm Numantec

Created at 27 Jul · 11:49 AM1 source↑ Market-relevant
IN SHORT

Goldman Sachs' private equity arm has agreed to acquire control of Italian medical equipment maker Numantec from White Bridge Investment. The deal is expected to close in the fourth quarter, with Numantec valued at around €700 million.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

€700 millionNumantec valuation
600Numantec employees
7Numantec manufacturing facilities

Who's Involved

Goldman Sachs Alternatives
Private equity arm acquiring control of Numantec
Numantec
Italian medical equipment maker
White Bridge Investment
Seller of Numantec
JPMorgan
Financial adviser to White Bridge Investment
Goldman Sachs International
Advisor to Goldman Sachs Alternatives
Goldman Sachs Alternatives buys control of Italian medtech firm Numantec

↳ Why This Matters

The acquisition by Goldman Sachs Alternatives highlights continued investor confidence in the steady revenue streams of the medical technology sector, even amidst broader macroeconomic uncertainty. It also signals potential for further consolidation and expansion within the European and U.S. medtech markets.

Key facts

  • Goldman Sachs Alternatives has agreed to acquire control of Italian medical equipment maker Numantec.
  • The seller is White Bridge Investment.
  • Numantec supplies healthcare products and drug-delivery devices and employs approximately 600 people.
  • The company operates seven manufacturing facilities across Europe and the United States.
  • The deal is valued at approximately €700 million.
  • The transaction is expected to close in the fourth quarter.

Goldman Sachs' private equity arm has agreed to acquire control of Italian medical equipment maker Numantec from White Bridge Investment. Numantec, based near Mantua, supplies a range of healthcare products and drug-delivery devices, employing approximately 600 people and operating seven manufacturing facilities across Europe and the United States.

White Bridge Investment had built Numantec through acquisitions, notably after a 2021 investment in Delta Med. While financial details were not disclosed, a source familiar with the matter indicated the sale valued Numantec at around €700 million. Under its new ownership, Numantec is expected to continue its expansion in Europe and strengthen its presence in the U.S., a market it entered last year by acquiring rival Health Line International.

The transaction is anticipated to conclude in the fourth quarter. JPMorgan served as the financial adviser to White Bridge Investment, while Goldman Sachs International advised its own alternatives division.

Frequently asked questions

Numantec is an Italian medical equipment maker that supplies a range of healthcare products and drug-delivery devices.

White Bridge Investment is selling its controlling stake in Numantec.

A person with knowledge of the matter told Reuters the sale valued Numantec at around €700 million.

The transaction is expected to close in the fourth quarter.

What Happens Next

01The transaction is expected to close in the fourth quarter.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

Goldman Sachs Alternatives agreed to acquire control of Italian medical equipment maker Numantec.
White Bridge Investment is selling its stake in Numantec.
Numantec supplies healthcare products and drug-delivery devices.
The company operates seven manufacturing facilities across Europe and the United States.
The sale valued Numantec at approximately €700 million.
The transaction is expected to close in the fourth quarter.

Sources

T1
Goldman Sachs Alternatives buys control of Italian medtech firm NumantecReuters

Related Stories

Saab secures $1.04 billion Middle East order for GlobalEye surveillance aircraft
27 Jul · 12:01 PM
Iwoca secures £250m debt facility amid sale speculation
27 Jul · 11:46 AM
Fairlife resumes production at 4 US plants after cyberattack
27 Jul · 11:09 AM
US private equity firm TPG to control NHS patient records
27 Jul · 10:51 AM
Brown-Forman board rejects Sazerac takeover proposal
26 Jul · 11:01 PM